Beyond multidrug-resistant tuberculosis in Europe: a TBNET study

作者：Guenther G; van Leth F; Altet N; Dedicoat M; Duarte R; Gualano G; Kunst H; Muylle I; Spinu V; Tiberi S; Viiklepp P; Lange C^*

来源：International Journal of Tuberculosis and Lung Disease, 2015, 19(12): 1524-1527.

DOI：10.5588/ijtld.15.0274

• Europe
• drug resistance
• MDR-TB
• TB
• extensively drug-resistant tuberculosis
• Tuberculosis Network European Trials

The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 'TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

• 出版日期2015-12